<DOC>
	<DOC>NCT02393807</DOC>
	<brief_summary>The current study will investigate the relative bioavailability of a spray dried dispersion solid dose formulation of PF 06260414 administered as a single oral dose of 30 mg of PF 06260414 relative to a single oral dose of 30 mg of PF 06260414 administered as a nanosuspension under fasted or fed conditions in healthy adult subjects.</brief_summary>
	<brief_title>The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects of non childbearing potential between the ages of 18 and 55 years, inclusive. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease Any condition possibly affecting drug absorption (eg, gastrectomy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>